CAP Profiles

Bio

Bio

Dr. Novoa received his bachelor and medical degrees from Harvard University. He completed his medical internship at Columbia University Medical Center and his dermatology residency at University Hospitals-Case Western Reserve School of Medicine before pursuing a dermatopathology fellowship at the University of Pennsylvania. Board certified in dermatology and dermatopathology, Dr. Novoa practices clinical dermatology and interprets slides as a dermatopathologist. His research interests include the medical applications of artificial intelligence, cutaneous lymphoma, and the cutaneous side effects of targeted therapies. Dr. Novoa served as co-PI on a research project featured on the cover of Nature Magazine. This work has appeared in the Wall Street Journal, Bloomberg Magazine, and PBS NOVA. He enjoys travel, reading, and Brazilian Jiu Jitsu.

Clinical Focus

  • Dermatology
  • Dermatopathology

Academic Appointments

Administrative Appointments

  • Associate Program Director, Stanford Dermatopathology Division (2017 - Present)

Boards, Advisory Committees, Professional Organizations

  • Member, Appropriate Use Criteria Committee, American Society of Dermatopathology (2016 - Present)
  • Fellow, American Academy of Dermatology (2013 - Present)
  • Fellow, American Society of Dermatopathology (2014 - Present)

Professional Education

  • Medical Education:Harvard Medical School (2009) MA
  • Board Certification: Dermatopathology, American Board of Dermatology (2014)
  • Board Certification: Dermatology, American Board of Dermatology (2013)
  • Residency, Case Western Reserve University School of Medicine- University Hospitals, Dermatology (2013)
  • Fellowship, University of Pennsylvania, Dermatopathology (2014)
  • Internship:Columbia University Medical CenterNYUnited States of America

Contact

  • Department of Pathology 300 Pasteur Dr Rm H1507 MC 5627 Stanford, CA 94305
    • Tel: (650) 723-6316
    Fax: (650) 725-7409

Links

Research & Scholarship

Current Research and Scholarly Interests

Recent advances in artificial intelligence stand poised to transform a number of human endeavors. A new approach, known as deep learning, harnesses large datasets, increased computing power, and convolutional neural networks to enable algorithms to discern complex patterns in raw data. These algorithms are widely used in autonomous vehicles, language translation, and image classification. Within medicine, these algorithms have been applied to a wide range of questions, ranging from detection of atrial fibrillation or breast cancer to prediction of ICU mortality. This same approach to pattern recognition can be applied to visual diagnosis of skin lesions, including melanoma.
Currently, melanoma is responsible for nearly 10,000 annual deaths in the United States alone, and early diagnosis is critical to cure. Furthermore, melanoma mortality demonstrates various disparities, with worse outcomes for patients of low socioeconomic status or those living in rural areas. In addition, keratinocyte carcinomas are the most common human malignancy, with over 5 million cases a year in the United States and thousands of deaths from aggressive local or metastatic disease.
Using deep learning techniques, we created a convolutional neural network (CNN) trained on 129,000 skin images and a morphological taxonomy composed of over 2000 disease categories. In a proof-of-concept study, our CNN demonstrated classification performance on par with 21 board-certified dermatologists across a range of tasks, including clinical and dermoscopic evaluation of melanocytic lesions. On expanded validation datasets, the algorithms showed comparable performance. More remains to be done, however, in order to validate this algorithm and examine its performance on prospective lesions. Furthermore, deep learning techniques struggle with 1) bias; 2) interpretability; 3) a lack of data; and 4) challenges with adversarial examples, where minute changes in angle or lighting can produce radically different outputs. In the next steps of our research, we seek to tackle these challenges while working on a prospective clinical trial of this technology in the real world.

Publications

All Publications

  • Automated Classification of Skin Lesions: From Pixels to Practice. The Journal of investigative dermatology Narla, A., Kuprel, B., Sarin, K., Novoa, R., Ko, J. 2018; 138 (10): 2108–10

    Abstract

    The letters "Interpretation of the Outputs of Deep Learning Model trained with Skin Cancer Dataset" and "Automated Dermatological Diagnosis: Hype or Reality?" highlight the opportunities, hurdles, and possible pitfalls with the development of tools that allow for automated skin lesion classification. The potential clinical impact of these advances relies on their scalability, accuracy, and generalizability across a range of diagnostic scenarios.

    View details for PubMedID 30244720

  • Dermatologist-level classification of skin cancer with deep neural networks. Nature Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., Thrun, S. 2017; 542 (7639): 115-118

    Abstract

    Skin cancer, the most common human malignancy, is primarily diagnosed visually, beginning with an initial clinical screening and followed potentially by dermoscopic analysis, a biopsy and histopathological examination. Automated classification of skin lesions using images is a challenging task owing to the fine-grained variability in the appearance of skin lesions. Deep convolutional neural networks (CNNs) show potential for general and highly variable tasks across many fine-grained object categories. Here we demonstrate classification of skin lesions using a single CNN, trained end-to-end from images directly, using only pixels and disease labels as inputs. We train a CNN using a dataset of 129,450 clinical images-two orders of magnitude larger than previous datasets-consisting of 2,032 different diseases. We test its performance against 21 board-certified dermatologists on biopsy-proven clinical images with two critical binary classification use cases: keratinocyte carcinomas versus benign seborrheic keratoses; and malignant melanomas versus benign nevi. The first case represents the identification of the most common cancers, the second represents the identification of the deadliest skin cancer. The CNN achieves performance on par with all tested experts across both tasks, demonstrating an artificial intelligence capable of classifying skin cancer with a level of competence comparable to dermatologists. Outfitted with deep neural networks, mobile devices can potentially extend the reach of dermatologists outside of the clinic. It is projected that 6.3 billion smartphone subscriptions will exist by the year 2021 (ref. 13) and can therefore potentially provide low-cost universal access to vital diagnostic care.

    View details for DOI 10.1038/nature21056

    View details for PubMedID 28117445

  • Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Updates on Classification and Management DERMATOLOGIC CLINICS Soleymani, T., Aasi, S. Z., Novoa, R., Hollmig, S. 2019; 37 (3): 253-+

    View details for DOI 10.1016/j.det.2019.02.001

    View details for Web of Science ID 000470954400004

  • Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management. Dermatologic clinics Soleymani, T., Aasi, S. Z., Novoa, R., Hollmig, S. T. 2019; 37 (3): 253–59

    Abstract

    Atypical fibroxanthoma and undifferentiated pleomorphic sarcoma, or pleomorphic dermal sarcoma, are rare malignant cutaneous neoplasms existing along a clinicopathologic spectrum. Although these tumors share many similarities, recognition of distinguishing characteristics may predict differences in clinical behavior and outcomes. Salient features defining atypical fibroxanthoma include superficial tumors with minimal high-risk histologic features. Deeper tumors with high-risk histologic features are often clinically aggressive and should be appropriately designated as pleomorphic dermal sarcoma. Surgery remains gold standard in management; tumor extirpation with complete margin control is critical. In the high-risk tumor cohort, comprehensive evaluation and multidisciplinary management is paramount for optimal outcomes.

    View details for PubMedID 31084719

  • Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma PIGMENT CELL & MELANOMA RESEARCH Sargen, M. R., Cloutier, J. M., Sarin, K. Y., Rieger, K. E., Chu, P., Swetter, S. M., Novoa, R. A. 2019; 32 (3): 474–78

    View details for DOI 10.1111/pcmr.12768

    View details for Web of Science ID 000465607700016

  • Introduction, Dermatology, Data, and Informatics. Seminars in cutaneous medicine and surgery Novoa, R. A. 2019; 38 (1): E1–E8

    View details for PubMedID 31051016

  • Artificial intelligence and dermatology: opportunities, challenges, and future directions. Seminars in cutaneous medicine and surgery Schlessinger, D. I., Chhor, G., Gevaert, O., Swetter, S. M., Ko, J., Novoa, R. A. 2019; 38 (1): E31–37

    Abstract

    The application of artificial intelligence (AI) to medicine has considerable potential within dermatology, where the majority of diagnoses are based on visual pattern recognition. Opportunities for AI in dermatology include the potential to automate repetitive tasks; optimize time-consuming tasks; extend limited medical resources; improve interobserver reliability issues; and expand the diagnostic toolbox of dermatologists. To achieve the full potential of AI, however, developers must aim to create algorithms representing diverse patient populations; ensure algorithm output is ultimately interpretable; validate algorithm performance prospectively; preserve human-patient interaction when necessary; and demonstrate validity in the eyes of regulatory bodies.

    View details for PubMedID 31051021

  • Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. Pigment cell & melanoma research Sargen, M. R., Cloutier, J. M., Sarin, K. Y., Rieger, K. E., Chu, P., Swetter, S. M., Novoa, R. A. 2019

    Abstract

    Protein biomarkers for diagnosis and prognosis are currently lacking for melanoma, which predominantly relies on histologic features for diagnosis (cytologic and nuclear pleomorphism, growth pattern) and staging (Breslow depth, ulceration). In many cases, the histology of the primary tumor is an unreliable predictor of tumor behavior, and consequently sentinel lymph node biopsy along with imaging studies are often necessary to predict likelihood of mortality from disease. This article is protected by copyright. All rights reserved.

    View details for PubMedID 30672662

  • Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. Journal of the American Academy of Dermatology Task Force/Committee Members, Vidal, C. I., Armbrect, E. A., Andea, A. A., Bohlke, A. K., Comfere, N. I., Hughes, S. R., Kim, J., Kozel, J. A., Lee, J. B., Linos, K., Litzner, B. R., Missall, T. A., Novoa, R. A., Sundram, U., Swick, B. L., Hurley, M. Y., Rating Panel, Alam, M., Argenyi, Z., Duncan, L. M., Elston, D. M., Emanuel, P. O., Ferringer, T., Fung, M. A., Hosler, G. A., Lazar, A. J., Lowe, L., Plaza, J. A., Prieto, V. G., Robinson, J. K., Schaffer, A., Subtil, A., Wang, W. 2019; 80 (1): 189

    Abstract

    BACKGROUND: Appropriate use criteria (AUC) provide physicians guidance in test selection, and can affect health care delivery, reimbursement policy, and physician decision-making.OBJECTIVES: The American Society of Dermatopathology, with input from the American Academy of Dermatology and the College of American Pathologists, sought to develop AUC in dermatopathology.METHODS: The RAND/UCLA appropriateness methodology, which combines evidence-based medicine, clinical experience, and expert judgment, was used to develop AUC in dermatopathology.RESULTS: With the number of ratings predetermined at 3, AUC were developed for 211 clinical scenarios involving 12 ancillary studies. Consensus was reached for 188 (89%) clinical scenarios, with 93 (44%) considered "usually appropriate" and 52 (25%) "rarely appropriate" and 43 (20%) having "uncertain appropriateness."LIMITATIONS: The methodology requires a focus on appropriateness without comparison between tests and irrespective of cost.CONCLUSIONS: The ultimate decision to order specific tests rests with the physician and is one where the expected benefit exceeds the negative consequences. This publication outlines the recommendations of appropriateness-the AUC for 12 tests used in dermatopathology. Importantly, these recommendations may change considering new evidence. Results deemed "uncertain appropriateness" and where consensus was not reached may benefit from further research.

    View details for PubMedID 29689323

  • Evidence behind the use of molecular tests in melanocytic lesions and practice patterns of these tests by dermatopathologists JOURNAL OF CUTANEOUS PATHOLOGY Emanuel, P. O., Andea, A. A., Vidal, C. I., Missall, T. A., Novoa, R. A., Bohlke, A. K., Hughes, S. R., Hurley, M. Y., Kim, J. 2018; 45 (11): 839–46

    Abstract

    The gold standard for the diagnosis of melanocytic lesions is histologic examination. However, as histologic examination can have its limitations, there are many clinical scenarios in which additional testing may be appropriate in an attempt to render a definitive diagnosis.A literature review for three ancillary tests-comparative genomic hybridization (CGH)/single-nucleotide polymorphism (SNP) array, fluorescence in situ hybridization (FISH), and gene expression profiling by quantitative reverse transcription polymerase chain reaction (qRT-PCR)-was compiled and current use patterns were tabulated. Survey of the practice patterns of these tests by dermatopathologists was also accessed in the attendees of the American Society of Dermatopathology Annual Meeting (Chicago, 2016).Here we summarize the use of these molecular tests in melanocytic lesions. We found that 54.4% of the respondents surveyed utilize (or expect consultants to utilize) molecular testing of melanocytic lesions in their practice when appropriate.CGH/SNP arrays, FISH testing, and qRT-PCR applied to melanocytic lesions have allowed for more accurate classification. Just over half of those surveyed use molecular testing for melanocytic lesion with the majority sending their cases out for completion of the molecular test.

    View details for PubMedID 30039879

  • Paraneoplastic granulomatous dermatitis in a patient with Hodgkin's disease: a diagnostic pitfall. BMJ case reports Tabata, M. M., Novoa, R. A., Martires, K. J. 2018; 2018

    Abstract

    The association of malignant lymphomas with non-necrotic epithelioid granulomas has been reported rarely since 1977. Hodgkin's disease-associated widespread cutaneous granuloma annulare (GA) has been reported in only eight patients. We report the second case of subcutaneous GA associated with Hodgkin's disease. A 73-year-old man with Epstein-Barr virus-associated Hodgkin's lymphoma and paraneoplastic subcutaneous GA, presented 3months after the diagnosis of malignancy. Examination revealed a large, broad erythematous, indurated, subcutaneous plaque spanning the majority of the left lower back and flank with no associated symptoms. Initial biopsy was suggestive of morphea. Prompted by positron emission tomography (PET) findings of increased fluorodeoxyglucose (FDG) uptake, a second, deeper biopsy was performed, revealing subcutaneous palisaded granulomatous dermatitis. After complete workup, the diagnosis most strongly suggested subcutaneous GA. This case highlights the importance of deep incisional biopsies, the fluorodeoxyglucose - positron emission tomography (FDG-PET) findings in GA and the rare association of GA with Hodgkin's disease which may signal the presence of malignancy.

    View details for PubMedID 30100570

  • Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology JOURNAL OF CUTANEOUS PATHOLOGY Vidal, C. I., Armbrect, E. A., Andea, A. A., Bohlke, A. K., Comfere, N. I., Hughes, S. R., Kim, J., Kozel, J. A., Lee, J. B., Linos, K., Litzner, B. R., Missall, T. A., Novoa, R. A., Sundram, U., Swick, B. L., Hurley, M., Alam, M., Argenyi, Z., Duncan, L. M., Elston, D. M., Emanuel, P. O., Ferringer, T., Fung, M. A., Hosler, G. A., Lazar, A. J., Lowe, L., Plaza, J. A., Prieto, V. G., Robinson, J. K., Schaffer, A., Subtil, A., Wang, W., Task Force Comm, Rating Panel 2018; 45 (8): 563–80

    Abstract

    Appropriate use criteria (AUC) provide physicians guidance in test selection, and can affect health care delivery, reimbursement policy and physician decision-making.The American Society of Dermatopathology, with input from the American Academy of Dermatology and the College of American Pathologists, sought to develop AUC in dermatopathology.The RAND/UCLA appropriateness methodology, which combines evidence-based medicine, clinical experience and expert judgment, was used to develop AUC in dermatopathology.With the number of ratings predetermined at 3, AUC were developed for 211 clinical scenarios involving 12 ancillary studies. Consensus was reached for 188 (89%) clinical scenarios, with 93 (44%) considered "usually appropriate," 52 (25%) "rarely appropriate" and 43 (20%) "uncertain appropriateness."The methodology requires a focus on appropriateness without comparison between tests and irrespective of cost.The ultimate decision of when to order specific test rests with the physician and is one where the expected benefit exceeds the negative consequences. This publication outlines the recommendations of appropriateness-AUC for 12 tests used in dermatopathology. Importantly, these recommendations may change considering new evidence. Results deemed "uncertain appropriateness" and where consensus was not reached may benefit from further research.

    View details for PubMedID 29566273

  • Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma JOURNAL OF INVESTIGATIVE DERMATOLOGY Rahbar, Z., Li, S., Tavallaee, M., Novoa, R. A., Kim, J., Kim, Y. H. 2018; 138 (5): 1204–6

    View details for PubMedID 29247659

  • Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides. Journal of cutaneous pathology Cedeno-Laurent, F., Wysocka, M., Obstfeld, A. E., Novoa, R. A., Vittorio, C. C., Kim, E. J., Weng, W., Rook, A. H. 2017

    Abstract

    Loss of CD26 surface expression on the circulating malignant T-cell is the most widely accepted diagnostic marker in patients with leukemic cutaneous T-cell lymphoma (CTCL). CTCL cases with reemergence of CD7 and/or CD26 surface expression are unusual and of uncertain prognosis. We report the case of an erythrodermic leukemic mycosis fungoides patient who had achieved temporary remission after a several months on multimodality immunotherapy and extracorporeal photopheresis, but who relapsed with aggressive disease phenotypically characterized by CD4+ T-cells with high CD26 expression. Polymerase chain reaction (PCR) studies and high throughput sequencing analyses from peripheral blood mononuclear cells at presentation and relapse consistently showed an identical clonal T-cell receptor (TCR) suggesting evolution of her original malignant clone which lacked CD26 expression. Interestingly, quantitative expression of the sialomucin, CD164, mirrored her clinical picture, thus favoring its reliability as a novel biomarker in CTCL.

    View details for DOI 10.1111/cup.12899

    View details for PubMedID 28083948

  • Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy. Journal of cutaneous pathology Dai, J., Kunder, C. A., Chu, E. Y., Chan, E. F., Egan, C. L., Novoa, R. A. 2017

    Abstract

    Treatment with BRAF inhibitors may lead to paradoxical mitogen-activated protein kinase (MAPK) pathway activation and accelerated tumorigenesis in cells with preexisting oncogenic hits. This phenomenon manifests clinically in the development of squamous cell carcinomas (SCCs) and keratoacanthomas (KAs) in patients treated with BRAF inhibitors. Cases of extracutaneous malignancies associated with BRAF inhibitors have also been reported. We present a case of a patient who developed a cutaneous angiosarcoma 6 months after initiation of vemurafenib therapy. Next-generation sequencing (NGS) revealed a mutation in RET, which lies upstream of the MAPK pathway. This case highlights that treatment with BRAF inhibitors may promote the accelerated growth of secondary malignancies. Physician awareness of the spectrum of secondary malignancies associated with BRAF inhibitor treatment will support their early detection and treatment.

    View details for PubMedID 28796396

  • Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma PEDIATRIC DERMATOLOGY Jaju, P., Novoa, R. A., Swetter, S. M., Sarin, K. Y. 2017; 34 (1): E35-E36

    Abstract

    We describe the case of a 26-year-old woman with a history of congenital ichthyosiform erythroderma (CIE) who initially presented with a stage IIA amelanotic melanoma on her forearm that was surgically excised. We also review the literature on CIE-associated skin cancers and discuss the possible contribution of ichthyosis to the risk of cutaneous malignancies. Our findings emphasize the importance of close lifelong skin cancer screening in individuals with CIE and highlight the unique malignancy risk of these individuals.

    View details for DOI 10.1111/pde.13012

    View details for Web of Science ID 000393955600008

  • Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma. Pediatric dermatology Jaju, P., Novoa, R. A., Swetter, S. M., Sarin, K. Y. 2016

    Abstract

    We describe the case of a 26-year-old woman with a history of congenital ichthyosiform erythroderma (CIE) who initially presented with a stage IIA amelanotic melanoma on her forearm that was surgically excised. We also review the literature on CIE-associated skin cancers and discuss the possible contribution of ichthyosis to the risk of cutaneous malignancies. Our findings emphasize the importance of close lifelong skin cancer screening in individuals with CIE and highlight the unique malignancy risk of these individuals.

    View details for DOI 10.1111/pde.13012

    View details for PubMedID 27813222

  • Low-Dose Radiotherapy for Primary Cutaneous Anaplastic Large-Cell Lymphoma While on Low-Dose Methotrexate CUTIS Cornejo, C. M., Novoa, R. A., Krisch, R. E., Kim, E. J. 2016; 98 (4): 253-256

    Abstract

    Primary cutaneous anaplastic large-cell lymphoma (pcALCL) is part of a spectrum of CD30+ primary cutaneous lymphoproliferative disorders (pcLPDs) that also includes lymphomatoid papulosis (LyP). Localized radiotherapy at doses of 34 to 44 Gy is first-line treatment of pcALCL, but the use of low-dose radiotherapy for pcALCL has not been reported. We present the case of a patient with a history of pcALCL/LyP who was treated with low-dose radiotherapy while on oral low-dose methotrexate (MTX) once weekly. This report suggests that low-dose radiotherapy can be an effective palliative treatment of pcALCL. Low-dose radiotherapy may offer certain advantages over traditional radiotherapy, such as a more economical and efficient treatment for patients, potentially fewer short-term and long-term side effects, and the potential for concomitant use with low-dose MTX.

    View details for Web of Science ID 000388917900015

    View details for PubMedID 27874877

  • Epidermotropic metastasis of primary lung adenocarcinoma. Journal of cutaneous pathology Scott, G. D., Kwong, B. Y., Novoa, R. A. 2016; 43 (9): 798-801

    Abstract

    Cutaneous metastasis of lung cancer is a rare event and usually portends a grim prognosis. Several cases of lung cancer with cutaneous metastasis have been reported, but these have been largely limited to the dermis. Here we describe a unique case of cutaneous metastatic lung adenocarcinoma largely limited to the epidermis, mimicking Paget's disease or a cutaneous adnexal tumor.

    View details for DOI 10.1111/cup.12741

    View details for PubMedID 27234927

  • Carpet beetle dermatitis: a possibly under-recognized entity INTERNATIONAL JOURNAL OF DERMATOLOGY MacArthur, K. M., Richardson, V., Novoa, R. A., Stewart, C. L., Rosenbach, M. 2016; 55 (5): 577-579

    View details for DOI 10.1111/ijd.12952

    View details for Web of Science ID 000374003900035

    View details for PubMedID 26475226

  • Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. Journal of cutaneous pathology Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., Kwong, B. Y. 2016; 43 (4): 339-346

    Abstract

    Recent advances in the immunotherapeutic treatment of cancer have led to the development of multiple new directed therapies including monoclonal antibodies that block the immune checkpoint T-cell receptor programmed death 1 (PD-1) and the PD-1 ligand, programmed death ligand 1 (PD-L1). Various immune-related toxicities have been associated with these drugs including, most commonly, skin rashes.Five cases of lichenoid dermatitis, including one case of lichenoid mucositis and one case of lichen sclerosus, associated with anti-PD-L1 and anti-PD1 therapy were compared with three biopsies of non-drug-related lichen planus (LP) and three lichen planus-like keratoses (LPLK) used as controls.Histopathologic and immunophenotypic analysis of these lichenoid lesions demonstrated significantly greater histiocytic infiltrates than observed in control lichenoid reactions (p = 0.0134). We also observed increased spongiosis and epidermal necrosis. No significant differences were seen in expression of CD3, CD4:CD8, CD20, PD-1, CD25, Foxp3, CXCL13 and PD-L1 expression.These findings expand the literature of immune-related toxicities of PD-L1 and PD-1 blockade to include lichenoid dermatitis and lichenoid mucositis. Of note, these cutaneous side effects were amenable to topical treatment, without the need for medication dose reduction or discontinuation.

    View details for DOI 10.1111/cup.12666

    View details for PubMedID 26762844

  • Fistulizing Epstein-Barr virus-positive plasmablastic lymphoma in an HIV-positive man BRITISH JOURNAL OF DERMATOLOGY Rangel, J., Novoa, R., Morrison, C., Frank, D., Kovarik, C. 2016; 174 (2): 398-401

    Abstract

    Plasmablastic lymphoma (PBL) is an unusual subtype of non-Hodgkin lymphoma recently classified as a diffuse immunoblastic lymphoma with a plasma-cell immunophenotype. Originally described in the oral cavity of HIV-positive patients, it has also been recognized to occur rarely at other sites. We describe a previously unreported fistulizing presentation of Epstein-Barr virus (EBV)-positive PBL, reviewing its association with HIV-1 infection and its importance as an AIDS-defining malignancy.

    View details for DOI 10.1111/bjd.14089

    View details for Web of Science ID 000370014600029

    View details for PubMedID 26286218

  • Erythematous Plaques on the Buttock JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Tan, C. Z., Novoa, R., Chen, J. K. 2016; 315 (1): 79-80

    View details for DOI 10.1001/jama.2015.13562

    View details for PubMedID 26746461

  • Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Clinical lymphoma, myeloma & leukemia Leatham, H. W., Novoa, R., Liedtke, M., Kwong, B. Y. 2016; 16 (1): e1-5

    View details for DOI 10.1016/j.clml.2015.11.007

    View details for PubMedID 26708980

  • Acquired port-wine stain with superimposed eczema following penetrating abdominal trauma. Cutis Langenhan, J., Novoa, R. A., Pappas-Taffer, L. 2015; 96 (6): 391-394

    Abstract

    Port-wine stains (PWSs), or capillary malformations, are common congenital lesions, but acquired lesions rarely present in the setting of trauma. We present the case of an 18-year-old man who developed a PWS and associated localized eczema following penetrating trauma to the left abdomen. The diagnoses were confirmed on biopsy. The patient's eczema improved with topical steroids. Magnetic resonance imaging of PWSs is recommended in order to rule out deeper arteriovenous malformations. More research is needed to elucidate the connection between PWS pathophysiology and the development of eczema.

    View details for PubMedID 26761933

  • Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA-1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder PEDIATRIC DERMATOLOGY Boos, M. D., Lee, L. W., Freedman, J. L., Novoa, R. A., Chu, E. Y., Perman, M. J. 2015; 32 (5): E204-E207

    Abstract

    Children with trisomy 21 are prone to developing hematologic disorders, including transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL). The papulovesicular eruption of TMD provides an important clue to the diagnosis. In contrast, AMKL rarely has associated cutaneous findings. We report the case of a 22-month-old child with trisomy 21 who presented with the acute onset of diffusely scattered and crusted papules, plaques, and vesicles. A thorough infectious evaluation was negative and the patient was unresponsive to empiric antibiotic and antiinflammatory therapies. Complete blood count (CBC) was notable for mild pancytopenia, with a normal peripheral smear. Two weeks later he was reassessed and found to have a population of blasts on repeat CBC. Subsequent evaluation ultimately led to a diagnosis of AMKL. This is the first reported case of a cutaneous eruption in a young child with Down syndrome and transformed AMKL. When children with trisomy 21 present with the acute onset of crusted papules and vesicles that cannot be accounted for by an infectious etiology, a diagnosis of AMKL should be considered even in the absence of a history of TMD.

    View details for DOI 10.1111/pde.12643

    View details for Web of Science ID 000361184000003

    View details for PubMedID 26205501

  • Erythrodermic Leukemia Cutis in a Patient With Pre-B-Cell Acute Lymphoblastic Leukemia. American Journal of dermatopathology Novoa, R. A., Wanat, K. A., Rosenbach, M., Frey, N., Frank, D. M., Elenitsas, R. 2015; 37 (8): 650-652

    Abstract

    The clinical differential diagnosis of erythroderma is extensive and includes both benign and malignant causes. The authors present an exceptional case of erythroderma secondary to pre-B-cell lymphoblastic leukemia cutis, with diagnostic findings on biopsy.

    View details for DOI 10.1097/DAD.0000000000000240

    View details for PubMedID 25436918

  • Herlitz Junctional Epidermolysis Bullosa with a Novel Mutation in LAMB3 PEDIATRIC DERMATOLOGY Kittridge, A., Patel, R., Novoa, R., Tamburro, J. 2014; 31 (4): 530-532

    Abstract

    Herlitz junctional epidermolysis bullosa (H-JEB) is a rare, heritable mechanobullous disease that affects infants at birth and causes early death. This disease is primarily caused by compound heterozygous or homozygous mutations in one of three genes affecting the function of one of the three chains of the laminin-332 (formerly laminin-5) protein. Here we report a case of H-JEB with a novel heterozygous mutation in LAMB3,c.1597G>A (p.Ala533Thr). These findings attest to the molecular heterogeneity of JEB and emphasize the importance of genetic analysis to help make an accurate diagnosis, predict clinical prognosis, and identify phenotypic-genotypic relationships that may aid in prenatal diagnosis and genetic counseling for the future.

    View details for DOI 10.1111/pde.12018

    View details for Web of Science ID 000340598200037

    View details for PubMedID 23278291

  • Hypertensive Emergency, Matlike Telangiectasias, and Calciphylaxis in POEMS Syndrome JAMA DERMATOLOGY Novoa, R. A., Honda, K. S., Campagnaro, E., Gerstenblith, M. R. 2014; 150 (6): 667-669

    View details for DOI 10.1001/jamadermatol.2013.7256

    View details for Web of Science ID 000337095800028

    View details for PubMedID 24718670

  • Cutaneous epithelioid melanocytic neurofibroma arising in a patient with neurofibromatosis-1 JOURNAL OF CUTANEOUS PATHOLOGY Novoa, R. A., Kovarik, C. L., Low, D. W., Argenyi, Z. 2014; 41 (5): 457-461

    Abstract

    Tumors expressing both melanocytic and neural features can pose a diagnostic challenge to the dermatopathologist and provoke questions regarding their lineage. We report a case of a tumor arising on the right cheek of a 9-year-old boy with neurofibromatosis type 1 (NF-1). This neoplasm featured nests of non-pigmented epithelioid cells arising within a neurofibroma. The entire tumor stained strongly with S100, whereas the epithelioid population stained with MART-1, HMB-45 and MiTF. The neoplasm shows only scattered Ki-67 positivity. This tumor represents a neurofibroma with portions that have undergone melanocytic differentiation (melanocytic neurofibroma). This exceedingly rare tumor represents a distinct entity from neurotized melanocytic nevi, combined melanocytic nevi or pigmented neurofibromas and provides further evidence that melanocytes arise indirectly from ventromedial neural crest-derived Schwann cell precursors.

    View details for DOI 10.1111/cup.12297

    View details for Web of Science ID 000337515700008

    View details for PubMedID 24472086

  • Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Paun, O., Phillips, T., Fu, P., Novoa, R. A., Honda, K. S., Lug, K. Q., Lazarus, H. M. 2013; 19 (8): 1204-1209

    Abstract

    The utility of cutaneous biopsies in directing the management of post-hematopoietic cell transplantation (HCT) eruptions remains uncertain. We retrospectively analyzed 439 consecutive HCT procedures for malignant hematologic disorders performed at our institution between January 2005 and December 2012; 192 patients underwent 430 cutaneous biopsies. The clinical and dermatopathologic diagnosis differed in 240 cases (56%). Biopsy results led to a change in therapy in 69 (16%) episodes. Seventeen of 69 management changes occurred in response to a clinical diagnosis of graft-versus-host disease and resulted in augmentation of systemic immunosuppression. The management was modified with similar frequencies with respect to concordance or discordance between the clinical and histopathologic diagnosis (P = .51). We used classification and regression tree (CART) analysis, a decision-modeling technique, to predict the biopsy yield as expressed by impact on clinical management in the allogeneic and autologous setting. The models were cross-validated and then tested against a validation subset, and they maintained a high negative predictive value and high specificity. Although skin biopsies may not be mandatory for either diagnostic or therapeutic reasons, in carefully chosen circumstances, this procedure can yield extremely important data. We believe a prospective study should be undertaken to evaluate current practice data and to validate our decision tree models.

    View details for DOI 10.1016/j.bbmt.2013.05.006

    View details for Web of Science ID 000322607000013

    View details for PubMedID 23688396

  • Acneiform eruptions associated with vemurafenib JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Petukhova, T. A., Novoa, R. A., Honda, K., Koon, H. B., Gerstenblith, M. R. 2013; 68 (3): E97-E99

    View details for DOI 10.1016/j.jaad.2012.09.015

    View details for Web of Science ID 000314823100006

    View details for PubMedID 23394928

  • Vasculitis and panniculitis associated with vemurafenib JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Novoa, R. A., Honda, K., Koon, H. B., Gerstenblith, M. R. 2012; 67 (6): E271-E272

    View details for DOI 10.1016/j.jaad.2012.05.019

    View details for Web of Science ID 000312131200013

    View details for PubMedID 23158633

  • IL-17 and Regulatory Cytokines (IL-10 and IL-27) in L-braziliensis Infection PARASITE IMMUNOLOGY NOVOA, R., Bacellar, O., Nascimento, M., Cardoso, T. M., Ramasawmy, R., OLIVEIRA, W. N., Schriefer, A., Carvalho, E. M. 2011; 33 (2): 132-136

    Abstract

    Cutaneous leishmaniasis (CL) is characterized by high production of pro-inflammatory cytokines and development of pathology. Individuals with subclinical L. braziliensis infection (SC) have a positive skin test to leishmania, but do not develop disease. We evaluated whether the downregulation of inflammatory response in SC is mediated by IL-10 and IL-27 and whether IL-17 is associated with control of infection. Participants include SC individuals, patients with CL and healthy subjects. Cytokines protein and mRNA were detected by ELISA and real-time PCR. IFN-γ and TNF-α levels were higher in CL than in SC group. The IL-10 levels and mRNA for IL-10 were similar in both SC and CL. mRNA for IL-27 was increased in cells from SC after stimulation with L. braziliensis antigen. There was a tendency for increased levels of IL-17 in SC compared to CL. The weak type 1 immune response observed in SC L. braziliensis infection is not because of the regulatory effects of IL-10 and IL-27. The control of Leishmania infection may be mediated by innate immune response with participation of IL-17. The results from this pilot study warrant further larger studies to investigate the potential contributions of IL-17 and IL-27 to the control of L. braziliensis infection.

    View details for DOI 10.1111/j.1365-3024.2010.01256.x

    View details for Web of Science ID 000286208100005

    View details for PubMedID 21226726

  • Ecstasy use and its association with sexual behaviors among drug users in New York City JOURNAL OF COMMUNITY HEALTH Novoa, R. A., Ompad, D. C., Wu, Y. F., Vlahov, D., Galea, S. 2005; 30 (5): 331-343

    Abstract

    In the past two decades, recreational use of ecstasy has become a growing concern in the United States, although most studies assessing ecstasy use have focused on white, middle-class adolescents who use ecstasy during raves and in clubs. We assessed the prevalence of recent ecstasy use among predominantly minority heroin, cocaine, and crack users in New York City and the association between ecstasy and sexual risk above and beyond that of the other drugs. Between 2002 and 2004, injection and non-injection heroin, crack and cocaine users (N= 534) completed a risk behavior questionnaire that included items on ecstasy use. Logistic regression was used to investigate the relation between current ecstasy use and sexual behaviors. Of 534 illicit drug users, 69.7% were aged 25 years or older, 65.2% were Hispanic, 27.9% Black and 77.4% male; 36.7% were injectors. 17.2% of respondents reported recent (last six months) ecstasy use. In a multivariable logistic regression model, current ecstasy use was associated both with initiating sex before age 14 (adjusted odds ratio (AOR) = 1.51) and having two or more partners in the past two months (AOR = 1.86) after adjusting for age at study entry, current cocaine and marijuana use and being an injection drug user. This study suggests that ecstasy use may be more prevalent among urban drug users. Ecstasy use in urban settings, beyond clubs and raves, should continue to be monitored.

    View details for DOI 10.1007/s10900-005-5515-0

    View details for Web of Science ID 000231867700002

    View details for PubMedID 16175956